Clinical evaluation of GanJi formulation in prevention recurrence of radical resection of primary liver cancer

Phase 1

Recruiting

• Conditions: primary liver cancer

• Registration Number: ITMCTR1900002326
• Lead Sponsor: Shuguang Hospial Affiliated to Shanghai University of TCM

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) patients with primary liver cancer after radical resection (BCLC stage 0, stage A);
(2) patients within 3 months after surgical treatment (surgery, radiofrequency ablation);
(3) aged 18 to 65 years, gender is not limited;
(4) willing to accept Chinese medicine and/or integrated Chinese and western medicine treatment;
(5) sign informed consent.

Exclusion Criteria

(1) metastatic liver cancer patients, or concurrent with other cancer patients;
(2) Without radical surgery or with refractory ascites, hepatic encephalopathy, liver failure, portal vein embolism and other serious complications;
(3) accompanied by heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract serious primary disease; Or mentally ill;
(4) legally disabled persons, pregnant women or nursing women;
(5) allergy or multiple drug allergy patients;
(6) patients with molecular targeted anti-tumor drugs (sorafenib).

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
recurrence rate;Survival period;

Secondary Outcome Measures

Name	Time	Method
MRI;Intestinal flora;Quality of Life Scale;liver function;Child-pugh grading;AFP;Fatality rate;